Advanced Accelerator Applications

Advanced Accelerator Applications (AAA) (NASDAQ: AAAP) is a pharmaceutical group specialised in the field of Molecular Nuclear Medicine. The group operates in all three segments of Molecular Nuclear Medicine (PET, SPECT and Therapy) to diagnose and treat serious conditions in the fields of oncology (cancer), neurology, cardiology, infectious and inflammatory diseases.

Molecular Nuclear Medicine is a medical specialty using small amounts of radioactive materials, called radiopharmaceuticals, to diagnose and treat disease. In nuclear medicine imaging, the radiopharmaceuticals are detected by special types of cameras (PET and SPECT) that work with computers to provide very precise pictures of the area of the body being imaged. Nuclear medicine can be used to treat certain types of cancer and other diseases.

Molecular Imaging allows physicians to see how the body is functioning and to measure its chemical and biological processes. Nuclear medicine procedures can often identify abnormalities very early in the progress of a disease — long before many medical problems are apparent with other diagnostic tests.

AAA was created in 2002 by Italian physicist Stefano Buono to exploit a patent from the European Organization for Nuclear Research (CERN). Today AAA trades on the Nasdaq Global Select Market under the ticker “AAAP.” The first day of trading was 11 November 2015.

The group currently has 21 production and research & development facilities that manufacture both diagnostic and therapeutic Molecular Nuclear Medicine products, and over 530 employees in 13 countries (Belgium, France, Germany, Italy, Poland, Portugal, Spain, Switzerland, The Netherlands, UK, Israel, U.S. and Canada).